1
|
Mouawad N, Capasso G, Ruggeri E, Martinello L, Severin F, Visentin A, Facco M, Trentin L, Frezzato F. Is It Still Possible to Think about HSP70 as a Therapeutic Target in Onco-Hematological Diseases? Biomolecules 2023; 13:biom13040604. [PMID: 37189352 DOI: 10.3390/biom13040604] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/02/2023] [Revised: 03/21/2023] [Accepted: 03/26/2023] [Indexed: 03/30/2023] Open
Abstract
The search for molecules to be targeted that are involved in apoptosis resistance/increased survival and pathogenesis of onco-hematological malignancies is ongoing since these diseases are still not completely understood. Over the years, a good candidate has been identified in the Heat Shock Protein of 70kDa (HSP70), a molecule defined as “the most cytoprotective protein ever been described”. HSP70 is induced in response to a wide variety of physiological and environmental insults, allowing cells to survive lethal conditions. This molecular chaperone has been detected and studied in almost all the onco-hematological diseases and is also correlated to poor prognosis and resistance to therapy. In this review, we give an overview of the discoveries that have led us to consider HSP70 as a therapeutic target for mono- or combination-therapies in acute and chronic leukemias, multiple myeloma and different types of lymphomas. In this excursus, we will also consider HSP70 partners, such as its transcription factor HSF1 or its co-chaperones whose druggability could indirectly affect HSP70. Finally, we will try to answer the question asked in the title of this review considering that, despite the effort made by research in this field, HSP70 inhibitors never reached the clinic.
Collapse
|
2
|
Guo Y, Guo L, Su Y, Xiong Y. CRISPR-Cas system manipulating nanoparticles signal transduction for cancer diagnosis. WILEY INTERDISCIPLINARY REVIEWS. NANOMEDICINE AND NANOBIOTECHNOLOGY 2023; 15:e1851. [PMID: 36199268 DOI: 10.1002/wnan.1851] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/09/2022] [Revised: 07/30/2022] [Accepted: 08/10/2022] [Indexed: 11/05/2022]
Abstract
Early diagnosis of cancer is important to improve the survival rate and relieve patient pain. Sensitive detection of cancer related biomarkers in body fluids is a critical approach for the early diagnosis of cancer. The clustered regularly interspaced short palindromic repeat-associated protein (CRISPR-Cas) system has emerged as a molecular manipulation technology because of its simple detection procedure, high base resolution, and isothermal signal amplification. Recently, various nanomaterials with unique optical and electrical characteristics have been introduced as the novel signal transducers to enhance the detection performance of CRISPR-Cas-based nanosensors. This review summarizes the working mechanisms of the CRISPR-Cas system for biosensing. It also enumerates the strategies of CRISPR-manipulated nanosensors based on various signal models for cancer diagnosis, including colorimetric, fluorescence, electrochemical, electrochemiluminescence, pressure, and other signals. Finally, the prospects and challenges of CRISPR-Cas-based nanosensors for cancer diagnostic are also discussed. This article is categorized under: Diagnostic Tools > Biosensing.
Collapse
Affiliation(s)
- Yuqian Guo
- State Key Laboratory of Food Science and Technology, Nanchang University, Nanchang, People's Republic of China
| | - Liang Guo
- Jiangxi-OAI Joint Research Institute, Nanchang University, Nanchang, People's Republic of China
| | - Yu Su
- School of Food Science and Technology, Nanchang University, Nanchang, People's Republic of China
| | - Yonghua Xiong
- State Key Laboratory of Food Science and Technology, Nanchang University, Nanchang, People's Republic of China.,School of Food Science and Technology, Nanchang University, Nanchang, People's Republic of China
| |
Collapse
|
3
|
Dezfouli AB, Stangl S, Foulds GA, Lennartz P, Pilkington GJ, Pockley AG, Multhoff G. Immunohistochemical, Flow Cytometric, and ELISA-Based Analyses of Intracellular, Membrane-Expressed, and Extracellular Hsp70 as Cancer Biomarkers. Methods Mol Biol 2023; 2693:307-324. [PMID: 37540444 DOI: 10.1007/978-1-0716-3342-7_23] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 08/05/2023]
Abstract
The major stress-inducible 70 kDa heat shock (stress) protein 70 (Hsp70) is frequently overexpressed in highly aggressive tumor cells and thus might serve as a tumor-specific biomarker of aggressive disease and/or therapeutic resistance. We have previously shown that, in contrast to normal cells, tumor cells present Hsp70 on their plasma membrane. In order to elucidate the role of intracellular, membrane-bound and extracellular Hsp70 as a potential tumor biomarker in cancer, herein we describe protocols for the staining of cytosolic Hsp70 in tumor formalin-fixed paraffin-embedded (FFPE) sections from patients with glioblastoma multiforme using immunohistochemistry, for detecting the expression of plasma membrane-bound Hsp70 by a range of cancer-derived cells using multi-parametric flow cytometry using the cmHsp70.1 monoclonal antibody (mAb) and for the measurement of free and vesicular-associated Hsp70 in the circulation of patients with cancer using a unique enzyme-linked immunosorbent assay (ELISA).
Collapse
Affiliation(s)
- Ali Bashiri Dezfouli
- Radiation Immuno-Oncology Group, Center for Translational Cancer Research Technische Universität München (TranslaTUM), Department of Radiation Oncology, Klinikum rechts der Isar, Technische Universität München (TUM), Munich, Germany
| | - Stefan Stangl
- Radiation Immuno-Oncology Group, Center for Translational Cancer Research Technische Universität München (TranslaTUM), Department of Radiation Oncology, Klinikum rechts der Isar, Technische Universität München (TUM), Munich, Germany
| | - Gemma A Foulds
- John van Geest Cancer Research Centre, School of Science and Technology, Nottingham Trent University, Nottingham, UK
| | - Philipp Lennartz
- Radiation Immuno-Oncology Group, Center for Translational Cancer Research Technische Universität München (TranslaTUM), Department of Radiation Oncology, Klinikum rechts der Isar, Technische Universität München (TUM), Munich, Germany
| | - Geoffrey J Pilkington
- Brain Tumour Research Centre, School of Pharmacy and Biomedical Sciences, Institute of Biomedical and Biomolecular Sciences, University of Portsmouth, Portsmouth, UK
| | - A Graham Pockley
- John van Geest Cancer Research Centre, School of Science and Technology, Nottingham Trent University, Nottingham, UK
| | - Gabriele Multhoff
- Radiation Immuno-Oncology Group, Center for Translational Cancer Research Technische Universität München (TranslaTUM), Department of Radiation Oncology, Klinikum rechts der Isar, Technische Universität München (TUM), Munich, Germany.
| |
Collapse
|
4
|
Fang HY, Stangl S, Marcazzan S, Carvalho MJB, Baumeister T, Anand A, Strangmann J, Huspenina JS, Wang TC, Schmid RM, Feith M, Friess H, Ntziachristos V, Multhoff G, Gorpas D, Quante M. Targeted Hsp70 fluorescence molecular endoscopy detects dysplasia in Barrett's esophagus. Eur J Nucl Med Mol Imaging 2022; 49:2049-2063. [PMID: 34882260 PMCID: PMC9016004 DOI: 10.1007/s00259-021-05582-y] [Citation(s) in RCA: 11] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/11/2021] [Accepted: 10/03/2021] [Indexed: 01/21/2023]
Abstract
PURPOSE The incidence of esophageal adenocarcinoma (EAC) has been increasing for decades without significant improvements in treatment. Barrett's esophagus (BE) is best established risk factor for EAC, but current surveillance with random biopsies cannot predict progression to cancer in most BE patients due to the low sensitivity and specificity of high-definition white light endoscopy. METHODS Here, we evaluated the membrane-bound highly specific Hsp70-specific contrast agent Tumor-Penetrating Peptide (Hsp70-TPP) in guided fluorescence molecular endoscopy biopsy. RESULTS Hsp70 was significantly overexpressed as determined by IHC in dysplasia and EAC compared with non-dysplastic BE in patient samples (n = 12) and in high-grade dysplastic lesions in a transgenic (L2-IL1b) mouse model of BE. In time-lapse microscopy, Hsp70-TPP was rapidly taken up and internalized by human BE dysplastic patient-derived organoids. Flexible fluorescence endoscopy of the BE mouse model allowed a specific detection of Hsp70-TPP-Cy5.5 that corresponded closely with the degree of dysplasia but not BE. Ex vivo application of Hsp70-TPP-Cy5.5 to freshly resected whole human EAC specimens revealed a high (> 4) tumor-to-background ratio and a specific detection of previously undetected tumor infiltrations. CONCLUSION In summary, these findings suggest that Hsp70-targeted imaging using fluorescently labeled TPP peptide may improve tumor surveillance in BE patients.
Collapse
Affiliation(s)
- Hsin-Yu Fang
- II Medizinische Klinik, Klinikum Rechts Der Isar, Technische Universität München, Munich, Germany
| | - Stefan Stangl
- Department of Radiation Oncology and Central Institute for Translational Cancer Research, (TranslaTUM), Technische Universität München, Munich, Germany
| | - Sabrina Marcazzan
- II Medizinische Klinik, Klinikum Rechts Der Isar, Technische Universität München, Munich, Germany ,Chair of Biological Imaging, School of Medicine, Technische Universität München, Munich, Germany; Helmholtz Zentrum München, Institute of Biological and Medical Imaging, Neuherberg, Germany
| | - Marcos J. Braz Carvalho
- II Medizinische Klinik, Klinikum Rechts Der Isar, Technische Universität München, Munich, Germany
| | - Theresa Baumeister
- II Medizinische Klinik, Klinikum Rechts Der Isar, Technische Universität München, Munich, Germany
| | - Akanksha Anand
- II Medizinische Klinik, Klinikum Rechts Der Isar, Technische Universität München, Munich, Germany
| | - Julia Strangmann
- II Medizinische Klinik, Klinikum Rechts Der Isar, Technische Universität München, Munich, Germany ,Innere Medizin II, Universitätsklinik Freiburg, Universität Freiburg, Freiburg im Breisgau, Germany
| | | | - Timothy C. Wang
- Department of Medicine, Columbia University Irving Medical Center, New York, NY USA
| | - Roland M. Schmid
- II Medizinische Klinik, Klinikum Rechts Der Isar, Technische Universität München, Munich, Germany
| | - Marcus Feith
- Chirurgische Klinik, Klinikum Rechts Der Isar, Technische Universität München, Munich, Germany
| | - Helmut Friess
- Chirurgische Klinik, Klinikum Rechts Der Isar, Technische Universität München, Munich, Germany
| | - Vasilis Ntziachristos
- Chair of Biological Imaging, School of Medicine, Technische Universität München, Munich, Germany; Helmholtz Zentrum München, Institute of Biological and Medical Imaging, Neuherberg, Germany
| | - Gabriele Multhoff
- Department of Radiation Oncology and Central Institute for Translational Cancer Research, (TranslaTUM), Technische Universität München, Munich, Germany
| | - Dimitris Gorpas
- Chair of Biological Imaging, School of Medicine, Technische Universität München, Munich, Germany; Helmholtz Zentrum München, Institute of Biological and Medical Imaging, Neuherberg, Germany
| | - Michael Quante
- II Medizinische Klinik, Klinikum Rechts Der Isar, Technische Universität München, Munich, Germany ,Innere Medizin II, Universitätsklinik Freiburg, Universität Freiburg, Freiburg im Breisgau, Germany
| |
Collapse
|
5
|
Wu N, Wei Y, Pan L, Yang X, Qi H, Gao Q, Zhang C, Li CZ. Sensitive and rapid determination of heat shock protein 70 using lateral flow immunostrips and upconversion nanoparticle fluorescence probes. Analyst 2022; 147:3444-3450. [DOI: 10.1039/d2an00742h] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
Heat shock protein 70 (Hsp70), belonging to the heat shock protein (HSP) family, is reported to be a potential diagnostic biomarker.
Collapse
Affiliation(s)
- Nengying Wu
- Key Laboratory of Analytical Chemistry for Life Science of Shaanxi Province, School of Chemistry and Chemical Engineering, Shaanxi Normal University, Xi'an, 710062, P.R. China
- Guizhou Academy of Forestry, Guiyang, 550000, P.R. China
| | - Yuxi Wei
- Key Laboratory of Analytical Chemistry for Life Science of Shaanxi Province, School of Chemistry and Chemical Engineering, Shaanxi Normal University, Xi'an, 710062, P.R. China
| | - Lanlan Pan
- Key Laboratory of Analytical Chemistry for Life Science of Shaanxi Province, School of Chemistry and Chemical Engineering, Shaanxi Normal University, Xi'an, 710062, P.R. China
| | - Xiaolin Yang
- Key Laboratory of Analytical Chemistry for Life Science of Shaanxi Province, School of Chemistry and Chemical Engineering, Shaanxi Normal University, Xi'an, 710062, P.R. China
| | - Honglan Qi
- Key Laboratory of Analytical Chemistry for Life Science of Shaanxi Province, School of Chemistry and Chemical Engineering, Shaanxi Normal University, Xi'an, 710062, P.R. China
| | - Qiang Gao
- Key Laboratory of Analytical Chemistry for Life Science of Shaanxi Province, School of Chemistry and Chemical Engineering, Shaanxi Normal University, Xi'an, 710062, P.R. China
| | - Chengxiao Zhang
- Key Laboratory of Analytical Chemistry for Life Science of Shaanxi Province, School of Chemistry and Chemical Engineering, Shaanxi Normal University, Xi'an, 710062, P.R. China
| | - Chen-zhong Li
- Department of Biochemistry and Molecular Biology, Tulane University School of Medicine, Tulane University School of Medicine, New Orleans, LA, USA
| |
Collapse
|
6
|
Li WB, Stangl S, Klapproth A, Shevtsov M, Hernandez A, Kimm MA, Schuemann J, Qiu R, Michalke B, Bernal MA, Li J, Hürkamp K, Zhang Y, Multhoff G. Application of High-Z Gold Nanoparticles in Targeted Cancer Radiotherapy-Pharmacokinetic Modeling, Monte Carlo Simulation and Radiobiological Effect Modeling. Cancers (Basel) 2021; 13:5370. [PMID: 34771534 PMCID: PMC8582555 DOI: 10.3390/cancers13215370] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/29/2021] [Revised: 10/20/2021] [Accepted: 10/22/2021] [Indexed: 02/05/2023] Open
Abstract
High-Z gold nanoparticles (AuNPs) conjugated to a targeting antibody can help to improve tumor control in radiotherapy while simultaneously minimizing radiotoxicity to adjacent healthy tissue. This paper summarizes the main findings of a joint research program which applied AuNP-conjugates in preclinical modeling of radiotherapy at the Klinikum rechts der Isar, Technical University of Munich and Helmholtz Zentrum München. A pharmacokinetic model of superparamagnetic iron oxide nanoparticles was developed in preparation for a model simulating the uptake and distribution of AuNPs in mice. Multi-scale Monte Carlo simulations were performed on a single AuNP and multiple AuNPs in tumor cells at cellular and molecular levels to determine enhancements in the radiation dose and generation of chemical radicals in close proximity to AuNPs. A biologically based mathematical model was developed to predict the biological response of AuNPs in radiation enhancement. Although simulations of a single AuNP demonstrated a clear dose enhancement, simulations relating to the generation of chemical radicals and the induction of DNA strand breaks induced by multiple AuNPs showed only a minor dose enhancement. The differences in the simulated enhancements at molecular and cellular levels indicate that further investigations are necessary to better understand the impact of the physical, chemical, and biological parameters in preclinical experimental settings prior to a translation of these AuNPs models into targeted cancer radiotherapy.
Collapse
Affiliation(s)
- Wei Bo Li
- Institute of Radiation Medicine, Helmholtz Zentrum München-German Research Center for Environmental Health (GmbH), 85764 Neuherberg, Germany; (A.K.); (K.H.)
| | - Stefan Stangl
- Center for Translational Cancer Research, Technische Universität München (TranslaTUM), Klinikum Rechts der Isar, Einsteinstr. 25, 81675 Munich, Germany; (S.S.); (M.S.); (A.H.)
- Department of Radiation Oncology, Technishe Universität München (TUM), Klinikum Rechts der Isar, Ismaningerstr. 22, 81675 Munich, Germany
| | - Alexander Klapproth
- Institute of Radiation Medicine, Helmholtz Zentrum München-German Research Center for Environmental Health (GmbH), 85764 Neuherberg, Germany; (A.K.); (K.H.)
- Center for Translational Cancer Research, Technische Universität München (TranslaTUM), Klinikum Rechts der Isar, Einsteinstr. 25, 81675 Munich, Germany; (S.S.); (M.S.); (A.H.)
- Department of Radiation Oncology, Technishe Universität München (TUM), Klinikum Rechts der Isar, Ismaningerstr. 22, 81675 Munich, Germany
| | - Maxim Shevtsov
- Center for Translational Cancer Research, Technische Universität München (TranslaTUM), Klinikum Rechts der Isar, Einsteinstr. 25, 81675 Munich, Germany; (S.S.); (M.S.); (A.H.)
- Department of Radiation Oncology, Technishe Universität München (TUM), Klinikum Rechts der Isar, Ismaningerstr. 22, 81675 Munich, Germany
- Personalized Medicine Centre, Almazov National Medical Research Centre, 2 Akkuratova Str., 197341 Saint Petersburg, Russia
- Laboratory of Biomedical Nanotechnologies, Institute of Cytology of the Russian Academy of Sciences (RAS), Tikhoretsky Ave., 4, 194064 Saint Petersburg, Russia
| | - Alicia Hernandez
- Center for Translational Cancer Research, Technische Universität München (TranslaTUM), Klinikum Rechts der Isar, Einsteinstr. 25, 81675 Munich, Germany; (S.S.); (M.S.); (A.H.)
- Department of Radiation Oncology, Technishe Universität München (TUM), Klinikum Rechts der Isar, Ismaningerstr. 22, 81675 Munich, Germany
| | - Melanie A. Kimm
- Department of Diagnostic and Interventional Radiology, Technische Universität München (TUM), Klinikum Rechts der Isar, 81675 Munich, Germany;
- Department of Radiology, University Hospital, Ludwig-Maximilians-Universität München, 81337 Munich, Germany;
| | - Jan Schuemann
- Physics Division, Department of Radiation Oncology, Massachusetts General Hospital (MGH) & Harvard Medical School, Boston, MA 02114, USA;
| | - Rui Qiu
- Department of Engineering Physics, Tsinghua University, Beijing 100084, China;
| | - Bernhard Michalke
- Research Unit Analytical BioGeoChemistry, Helmholz Zentrum München-German Research Center for Environmental Health (GmbH), 85764 Neuherberg, Germany;
| | - Mario A. Bernal
- Gleb Wataghin Institute of Physics, State University of Campinas, Campinas 13083-859, SP, Brazil;
| | - Junli Li
- Department of Radiology, University Hospital, Ludwig-Maximilians-Universität München, 81337 Munich, Germany;
| | - Kerstin Hürkamp
- Institute of Radiation Medicine, Helmholtz Zentrum München-German Research Center for Environmental Health (GmbH), 85764 Neuherberg, Germany; (A.K.); (K.H.)
| | - Yibao Zhang
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Radiation Oncology, Peking University Cancer Hospital & Institute, Beijing 100142, China;
| | - Gabriele Multhoff
- Center for Translational Cancer Research, Technische Universität München (TranslaTUM), Klinikum Rechts der Isar, Einsteinstr. 25, 81675 Munich, Germany; (S.S.); (M.S.); (A.H.)
- Department of Radiation Oncology, Technishe Universität München (TUM), Klinikum Rechts der Isar, Ismaningerstr. 22, 81675 Munich, Germany
| |
Collapse
|
7
|
Vostakolaei MA, Hatami-Baroogh L, Babaei G, Molavi O, Kordi S, Abdolalizadeh J. Hsp70 in cancer: A double agent in the battle between survival and death. J Cell Physiol 2020; 236:3420-3444. [PMID: 33169384 DOI: 10.1002/jcp.30132] [Citation(s) in RCA: 49] [Impact Index Per Article: 9.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/19/2020] [Revised: 09/23/2020] [Accepted: 10/16/2020] [Indexed: 12/11/2022]
Abstract
The heat shock protein (Hsps) superfamily, also known as molecular chaperones, are highly conserved and present in all living organisms and play vital roles in protein fate. The HspA1A (Hsp70-1), called Hsp70 in this review, is expressed at low or undetectable levels in most unstressed normal cells, but numerous studies have shown that diverse types of tumor cells express Hsp70 at the plasma membrane that leads to resistance to programmed cell death and tumor progression. Hsp70 is released into the extracellular milieu in three forms including free soluble, complexed with cancer antigenic peptides, and exosome forms. Therefore, it seems to be a promising therapeutic target in human malignancies. However, a great number of studies have indicated that both intracellular and extracellular Hsp70 have a dual function. A line of evidence presented that intracellular Hsp70 has a cytoprotective function via suppression of apoptosis and lysosomal cell death (LCD) as well as that extracellular Hsp70 can promote tumorigenesis and angiogenesis. Other evidence showed intracellular Hsp70 can promote apoptosis and membrane-associated/extracellular Hsp70 can elicit antitumor innate and adaptive immune responses. Given the contradictory functions, as a "double agent," could Hsp70 be a promising tool in the future of targeted cancer therapies? To answer this question, in this review, we will discuss the functions of Hsp70 in cancers besides inhibition and stimulation strategies for targeting Hsp70 along with their challenges.
Collapse
Affiliation(s)
- Mehdi A Vostakolaei
- Digestive Diseases Research Center, Ardabil University of Medical Sciences, Ardabil, Iran.,Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
| | - Leila Hatami-Baroogh
- Department of Reproduction and Development, Royan Institute for Animal Biotechnology, ACER, Isfahan, Iran
| | - Ghader Babaei
- Department of Biochemistry, Urmia University Medical Sciences, Urmia, Iran
| | - Ommoleila Molavi
- Biotechnology Research Center, Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran
| | - Shirafkan Kordi
- Antimicrobial Resistance Research Center, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran.,Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran
| | - Jalal Abdolalizadeh
- Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.,Paramedical Faculty, Tabriz University of Medical Sciences, Tabriz, Iran
| |
Collapse
|
8
|
Aslan N, Ceylan B, Koç MM, Findik F. Metallic nanoparticles as X-Ray computed tomography (CT) contrast agents: A review. J Mol Struct 2020. [DOI: 10.1016/j.molstruc.2020.128599] [Citation(s) in RCA: 33] [Impact Index Per Article: 6.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
|
9
|
Kimm MA, Shevtsov M, Werner C, Sievert W, Zhiyuan W, Schoppe O, Menze BH, Rummeny EJ, Proksa R, Bystrova O, Martynova M, Multhoff G, Stangl S. Gold Nanoparticle Mediated Multi-Modal CT Imaging of Hsp70 Membrane-Positive Tumors. Cancers (Basel) 2020; 12:cancers12051331. [PMID: 32456049 PMCID: PMC7281090 DOI: 10.3390/cancers12051331] [Citation(s) in RCA: 20] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/15/2020] [Revised: 05/18/2020] [Accepted: 05/20/2020] [Indexed: 11/21/2022] Open
Abstract
Imaging techniques such as computed tomographies (CT) play a major role in clinical imaging and diagnosis of malignant lesions. In recent years, metal nanoparticle platforms enabled effective payload delivery for several imaging techniques. Due to the possibility of surface modification, metal nanoparticles are predestined to facilitate molecular tumor targeting. In this work, we demonstrate the feasibility of anti-plasma membrane Heat shock protein 70 (Hsp70) antibody functionalized gold nanoparticles (cmHsp70.1-AuNPs) for tumor-specific multimodal imaging. Membrane-associated Hsp70 is exclusively presented on the plasma membrane of malignant cells of multiple tumor entities but not on corresponding normal cells, predestining this target for a tumor-selective in vivo imaging. In vitro microscopic analysis revealed the presence of cmHsp70.1-AuNPs in the cytosol of tumor cell lines after internalization via the endo-lysosomal pathway. In preclinical models, the biodistribution as well as the intratumoral enrichment of AuNPs were examined 24 h after i.v. injection in tumor-bearing mice. In parallel to spectral CT analysis, histological analysis confirmed the presence of AuNPs within tumor cells. In contrast to control AuNPs, a significant enrichment of cmHsp70.1-AuNPs has been detected selectively inside tumor cells in different tumor mouse models. Furthermore, a machine-learning approach was developed to analyze AuNP accumulations in tumor tissues and organs. In summary, utilizing mHsp70 on tumor cells as a target for the guidance of cmHsp70.1-AuNPs facilitates an enrichment and uniform distribution of nanoparticles in mHsp70-expressing tumor cells that enables various microscopic imaging techniques and spectral-CT-based tumor delineation in vivo.
Collapse
Affiliation(s)
- Melanie A. Kimm
- Department of Diagnostic and Interventional Radiology, Klinikum rechts der Isar der Technischen Universität München, 81675 Munich, Germany; (M.A.K.); (E.J.R.)
| | - Maxim Shevtsov
- Central Institute for Translational Cancer Research (TranslaTUM), Klinikum rechts der Isar der Technischen Universität München, 81675 Munich, Germany; (M.S.); (C.W.); (W.S.); (W.Z.); (O.S.); (B.H.M.); (G.M.)
- Pavlov First Saint Petersburg State Medical University, 197022 St. Petersburg, Russia
- Institute of Cytology of the Russian Academy of Sciences (RAS), 194064 St. Petersburg, Russia; (O.B.); (M.M.)
| | - Caroline Werner
- Central Institute for Translational Cancer Research (TranslaTUM), Klinikum rechts der Isar der Technischen Universität München, 81675 Munich, Germany; (M.S.); (C.W.); (W.S.); (W.Z.); (O.S.); (B.H.M.); (G.M.)
| | - Wolfgang Sievert
- Central Institute for Translational Cancer Research (TranslaTUM), Klinikum rechts der Isar der Technischen Universität München, 81675 Munich, Germany; (M.S.); (C.W.); (W.S.); (W.Z.); (O.S.); (B.H.M.); (G.M.)
| | - Wu Zhiyuan
- Central Institute for Translational Cancer Research (TranslaTUM), Klinikum rechts der Isar der Technischen Universität München, 81675 Munich, Germany; (M.S.); (C.W.); (W.S.); (W.Z.); (O.S.); (B.H.M.); (G.M.)
| | - Oliver Schoppe
- Central Institute for Translational Cancer Research (TranslaTUM), Klinikum rechts der Isar der Technischen Universität München, 81675 Munich, Germany; (M.S.); (C.W.); (W.S.); (W.Z.); (O.S.); (B.H.M.); (G.M.)
- Institute for Advanced Studies, Department of Informatics, Technical University of Munich, 85748 Garching, Germany
| | - Bjoern H. Menze
- Central Institute for Translational Cancer Research (TranslaTUM), Klinikum rechts der Isar der Technischen Universität München, 81675 Munich, Germany; (M.S.); (C.W.); (W.S.); (W.Z.); (O.S.); (B.H.M.); (G.M.)
- Institute for Advanced Studies, Department of Informatics, Technical University of Munich, 85748 Garching, Germany
| | - Ernst J. Rummeny
- Department of Diagnostic and Interventional Radiology, Klinikum rechts der Isar der Technischen Universität München, 81675 Munich, Germany; (M.A.K.); (E.J.R.)
| | - Roland Proksa
- Philips GmbH Innovative Technologies, Research Laboratories, 22335 Hamburg, Germany;
| | - Olga Bystrova
- Institute of Cytology of the Russian Academy of Sciences (RAS), 194064 St. Petersburg, Russia; (O.B.); (M.M.)
| | - Marina Martynova
- Institute of Cytology of the Russian Academy of Sciences (RAS), 194064 St. Petersburg, Russia; (O.B.); (M.M.)
| | - Gabriele Multhoff
- Central Institute for Translational Cancer Research (TranslaTUM), Klinikum rechts der Isar der Technischen Universität München, 81675 Munich, Germany; (M.S.); (C.W.); (W.S.); (W.Z.); (O.S.); (B.H.M.); (G.M.)
| | - Stefan Stangl
- Central Institute for Translational Cancer Research (TranslaTUM), Klinikum rechts der Isar der Technischen Universität München, 81675 Munich, Germany; (M.S.); (C.W.); (W.S.); (W.Z.); (O.S.); (B.H.M.); (G.M.)
- Correspondence: ; Tel.: +49-89-4140-6013; Fax: +49-89-4140-4299
| |
Collapse
|
10
|
Membrane-Associated Heat Shock Proteins in Oncology: From Basic Research to New Theranostic Targets. Cells 2020; 9:cells9051263. [PMID: 32443761 PMCID: PMC7290778 DOI: 10.3390/cells9051263] [Citation(s) in RCA: 39] [Impact Index Per Article: 7.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/30/2020] [Revised: 05/16/2020] [Accepted: 05/18/2020] [Indexed: 12/13/2022] Open
Abstract
Heat shock proteins (HSPs) constitute a large family of conserved proteins acting as molecular chaperones that play a key role in intracellular protein homeostasis, regulation of apoptosis, and protection from various stress factors (including hypoxia, thermal stress, oxidative stress). Apart from their intracellular localization, members of different HSP families such as small HSPs, HSP40, HSP60, HSP70 and HSP90 have been found to be localized on the plasma membrane of malignantly transformed cells. In the current article, the role of membrane-associated molecular chaperones in normal and tumor cells is comprehensively reviewed with implications of these proteins as plausible targets for cancer therapy and diagnostics.
Collapse
|
11
|
Chanteloup G, Cordonnier M, Isambert N, Bertaut A, Hervieu A, Hennequin A, Luu M, Zanetta S, Coudert B, Bengrine L, Desmoulins I, Favier L, Lagrange A, Pages PB, Gutierrez I, Lherminier J, Avoscan L, Jankowski C, Rébé C, Chevriaux A, Padeano MM, Coutant C, Ladoire S, Causeret S, Arnould L, Charon-Barra C, Cottet V, Blanc J, Binquet C, Bardou M, Garrido C, Gobbo J. Monitoring HSP70 exosomes in cancer patients' follow up: a clinical prospective pilot study. J Extracell Vesicles 2020; 9:1766192. [PMID: 32595915 PMCID: PMC7301715 DOI: 10.1080/20013078.2020.1766192] [Citation(s) in RCA: 75] [Impact Index Per Article: 15.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/23/2020] [Revised: 03/26/2020] [Accepted: 04/21/2020] [Indexed: 12/19/2022] Open
Abstract
Exosomes are nanovesicles released by all cells that can be found in the blood. A key point for their use as potential biomarkers in cancer is to differentiate tumour-derived exosomes from other circulating nanovesicles. Heat shock protein-70 (HSP70) has been shown to be abundantly expressed by cancer cells and to be associated with bad prognosis. We previously showed that exosomes derived from cancer cells carried HSP70 in the membrane while those from non-cancerous cells did not. In this work, we opened a prospective clinical pilot study including breast and lung cancer patients to determine whether it was possible to detect and quantify HSP70 exosomes in the blood of patients with solid cancers. We found that circulating exosomal HSP70 levels, but not soluble HSP70, reflected HSP70 content within the tumour biopsies. Circulating HSP70 exosomes increased in metastatic patients compared to non-metastatic patients or healthy volunteers. Further, we demonstrated that HSP70-exosome levels correlated with the disease status and, when compared with circulating tumour cells, were more sensitive tumour dissemination predictors. Finally, our case studies indicated that HSP70-exosome levels inversely correlated with response to the therapy and that, therefore, monitoring changes in circulating exosomal HSP70 might be useful to predict tumour response and clinical outcome.
Collapse
Affiliation(s)
- Gaëtan Chanteloup
- Inserm, UMR 1231, label d’Excellence Ligue National contre le Cancer and Laboratoire d’Excellence LipSTIC, Dijon, France
- Faculty of Medicine and Pharmacy, University of Burgundy, Dijon, France
| | - Marine Cordonnier
- Inserm, UMR 1231, label d’Excellence Ligue National contre le Cancer and Laboratoire d’Excellence LipSTIC, Dijon, France
- Faculty of Medicine and Pharmacy, University of Burgundy, Dijon, France
| | - Nicolas Isambert
- Inserm U-1084, Pôle Régional de Cancérologie, CHU de Poitiers Poitiers Cedex – France, Université de Poitiers, Poitiers, France
| | - Aurélie Bertaut
- CHU Dijon-Bourgogne, Georges-François Leclerc Centre, CGFL, Dijon, France
| | - Alice Hervieu
- CHU Dijon-Bourgogne, Georges-François Leclerc Centre, CGFL, Dijon, France
| | - Audrey Hennequin
- CHU Dijon-Bourgogne, Georges-François Leclerc Centre, CGFL, Dijon, France
| | - Maxime Luu
- Centre d’investigation Clinique INSERM 1432, CHU Dijon-Bourgogne, Dijon, France
| | - Sylvie Zanetta
- CHU Dijon-Bourgogne, Georges-François Leclerc Centre, CGFL, Dijon, France
| | - Bruno Coudert
- CHU Dijon-Bourgogne, Georges-François Leclerc Centre, CGFL, Dijon, France
| | - Leila Bengrine
- CHU Dijon-Bourgogne, Georges-François Leclerc Centre, CGFL, Dijon, France
| | | | - Laure Favier
- CHU Dijon-Bourgogne, Georges-François Leclerc Centre, CGFL, Dijon, France
| | - Aurélie Lagrange
- CHU Dijon-Bourgogne, Georges-François Leclerc Centre, CGFL, Dijon, France
| | | | - Ivan Gutierrez
- Department of Thoracic Surgery, Dijon University Hospital, Dijon, France
| | - Jeanine Lherminier
- INRA, UMR1347 Agroécologie, ERL CNRS 6300, Plateforme DImaCell, Centre de Microscopie INRA/Université de Bourgogne, Dijon, France
| | - Laure Avoscan
- INRA, UMR1347 Agroécologie, ERL CNRS 6300, Plateforme DImaCell, Centre de Microscopie INRA/Université de Bourgogne, Dijon, France
| | | | - Cédric Rébé
- CHU Dijon-Bourgogne, Georges-François Leclerc Centre, CGFL, Dijon, France
| | | | | | - Charles Coutant
- CHU Dijon-Bourgogne, Georges-François Leclerc Centre, CGFL, Dijon, France
| | - Sylvain Ladoire
- CHU Dijon-Bourgogne, Georges-François Leclerc Centre, CGFL, Dijon, France
| | - Sylvain Causeret
- CHU Dijon-Bourgogne, Georges-François Leclerc Centre, CGFL, Dijon, France
| | - Laurent Arnould
- CHU Dijon-Bourgogne, Georges-François Leclerc Centre, CGFL, Dijon, France
| | | | - Vanessa Cottet
- Centre d’investigation Clinique INSERM 1432, CHU Dijon-Bourgogne, Dijon, France
| | - Julie Blanc
- CHU Dijon-Bourgogne, Georges-François Leclerc Centre, CGFL, Dijon, France
| | - Christine Binquet
- Centre d’investigation Clinique INSERM 1432, CHU Dijon-Bourgogne, Dijon, France
| | - Marc Bardou
- Centre d’investigation Clinique INSERM 1432, CHU Dijon-Bourgogne, Dijon, France
| | - Carmen Garrido
- Inserm, UMR 1231, label d’Excellence Ligue National contre le Cancer and Laboratoire d’Excellence LipSTIC, Dijon, France
- Faculty of Medicine and Pharmacy, University of Burgundy, Dijon, France
- CHU Dijon-Bourgogne, Georges-François Leclerc Centre, CGFL, Dijon, France
| | - Jessica Gobbo
- Inserm, UMR 1231, label d’Excellence Ligue National contre le Cancer and Laboratoire d’Excellence LipSTIC, Dijon, France
- Faculty of Medicine and Pharmacy, University of Burgundy, Dijon, France
- CHU Dijon-Bourgogne, Georges-François Leclerc Centre, CGFL, Dijon, France
- Centre d’investigation Clinique INSERM 1432, CHU Dijon-Bourgogne, Dijon, France
| |
Collapse
|
12
|
Li WB, Belchior A, Beuve M, Chen YZ, Di Maria S, Friedland W, Gervais B, Heide B, Hocine N, Ipatov A, Klapproth AP, Li CY, Li JL, Multhoff G, Poignant F, Qiu R, Rabus H, Rudek B, Schuemann J, Stangl S, Testa E, Villagrasa C, Xie WZ, Zhang YB. Intercomparison of dose enhancement ratio and secondary electron spectra for gold nanoparticles irradiated by X-rays calculated using multiple Monte Carlo simulation codes. Phys Med 2020; 69:147-163. [PMID: 31918367 DOI: 10.1016/j.ejmp.2019.12.011] [Citation(s) in RCA: 31] [Impact Index Per Article: 6.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/04/2019] [Revised: 11/29/2019] [Accepted: 12/15/2019] [Indexed: 12/22/2022] Open
Abstract
PURPOSE Targeted radiation therapy has seen an increased interest in the past decade. In vitro and in vivo experiments showed enhanced radiation doses due to gold nanoparticles (GNPs) to tumors in mice and demonstrated a high potential for clinical application. However, finding a functionalized molecular formulation for actively targeting GNPs in tumor cells is challenging. Furthermore, the enhanced energy deposition by secondary electrons around GNPs, particularly by short-ranged Auger electrons is difficult to measure. Computational models, such as Monte Carlo (MC) radiation transport codes, have been used to estimate the physical quantities and effects of GNPs. However, as these codes differ from one to another, the reliability of physical and dosimetric quantities needs to be established at cellular and molecular levels, so that the subsequent biological effects can be assessed quantitatively. METHODS In this work, irradiation of single GNPs of 50 nm and 100 nm diameter by X-ray spectra generated by 50 and 100 peak kilovoltages was simulated for a defined geometry setup, by applying multiple MC codes in the EURADOS framework. RESULTS The mean dose enhancement ratio of the first 10 nm-thick water shell around a 100 nm GNP ranges from 400 for 100 kVp X-rays to 600 for 50 kVp X-rays with large uncertainty factors up to 2.3. CONCLUSIONS It is concluded that the absolute dose enhancement effects have large uncertainties and need an inter-code intercomparison for a high quality assurance; relative properties may be a better measure until more experimental data is available to constrain the models.
Collapse
Affiliation(s)
- W B Li
- Institute of Radiation Medicine, Helmholtz Zentrum München - German Research Center for Environmental Health (GmbH), Ingolstädter Landstr. 1, 85764 Neuherberg, Germany.
| | - A Belchior
- Centro de Ciências e Tecnologias Nucleares, Instituto Superior Técnico, Universidade de Lisboa, Estrada Nacional 10, 2695-066 Bobadela LRS, Portugal
| | - M Beuve
- Institut de Physique Nucléaire de Lyon, Université de Lyon, Université Claude Bernard Lyon 1, CNRS/IN2P3 UMR 5822, Villeurbanne, France
| | - Y Z Chen
- Department of Engineering Physics, Tsinghua University, Beijing, China
| | - S Di Maria
- Centro de Ciências e Tecnologias Nucleares, Instituto Superior Técnico, Universidade de Lisboa, Estrada Nacional 10, 2695-066 Bobadela LRS, Portugal
| | - W Friedland
- Institute of Radiation Medicine, Helmholtz Zentrum München - German Research Center for Environmental Health (GmbH), Ingolstädter Landstr. 1, 85764 Neuherberg, Germany
| | - B Gervais
- Normandie University, ENSICAEN, UNICAEN, CEA, CNRS, CIMAP, UMR 6252, BP 5133, F-14070 Caen Cedex 05, France
| | - B Heide
- Karlsruhe Institute of Technology, Karlsruhe, Germany
| | - N Hocine
- Institut de Radioprotection et de Sûreté Nucléaire, Fontenay-Aux-Roses, France
| | - A Ipatov
- Alferov Federal State Budgetary Institution of Higher Education and Science Saint Petersburg National Research Academic University of the Russian Academy of Sciences, St. Petersburg, Russia
| | - A P Klapproth
- Institute of Radiation Medicine, Helmholtz Zentrum München - German Research Center for Environmental Health (GmbH), Ingolstädter Landstr. 1, 85764 Neuherberg, Germany; TranslaTUM, Klinikum rechts der Isar, Technische Universität München, Munich, Germany
| | - C Y Li
- Department of Engineering Physics, Tsinghua University, Beijing, China; Nuctech Company Limited, Beijing, China
| | - J L Li
- Department of Engineering Physics, Tsinghua University, Beijing, China
| | - G Multhoff
- TranslaTUM, Klinikum rechts der Isar, Technische Universität München, Munich, Germany
| | - F Poignant
- Institut de Physique Nucléaire de Lyon, Université de Lyon, Université Claude Bernard Lyon 1, CNRS/IN2P3 UMR 5822, Villeurbanne, France
| | - R Qiu
- Department of Engineering Physics, Tsinghua University, Beijing, China
| | - H Rabus
- Physikalisch-Technische Bundesanstalt, Braunschweig, Germany
| | - B Rudek
- Physikalisch-Technische Bundesanstalt, Braunschweig, Germany; Massachusetts General Hospital & Harvard Medical School, Department of Radiation Oncology, Boston, MA, USA
| | - J Schuemann
- Massachusetts General Hospital & Harvard Medical School, Department of Radiation Oncology, Boston, MA, USA
| | - S Stangl
- TranslaTUM, Klinikum rechts der Isar, Technische Universität München, Munich, Germany
| | - E Testa
- Institut de Physique Nucléaire de Lyon, Université de Lyon, Université Claude Bernard Lyon 1, CNRS/IN2P3 UMR 5822, Villeurbanne, France
| | - C Villagrasa
- Institut de Radioprotection et de Sûreté Nucléaire, Fontenay-Aux-Roses, France
| | - W Z Xie
- Department of Engineering Physics, Tsinghua University, Beijing, China
| | - Y B Zhang
- Peking University Cancer Hospital, Beijing, China
| |
Collapse
|
13
|
Elmallah MIY, Cordonnier M, Vautrot V, Chanteloup G, Garrido C, Gobbo J. Membrane-anchored heat-shock protein 70 (Hsp70) in cancer. Cancer Lett 2019; 469:134-141. [PMID: 31669516 DOI: 10.1016/j.canlet.2019.10.037] [Citation(s) in RCA: 45] [Impact Index Per Article: 7.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/16/2019] [Revised: 10/18/2019] [Accepted: 10/22/2019] [Indexed: 12/19/2022]
Abstract
Hsp70 is a highly conserved and inducible heat shock protein that belongs to the HSP70 family of molecular chaperones and plays a central role in protein homeostasis. The main function of Hsp70 is to protect cells from physiological, pathological and environmental insults, as it assists an ATP-dependent manner the process of protein folding. Since Hsp70 provides critical cell survival functions, cancer cells are assumed to rely on this chaperone. Strong evidence suggests that Hsp70 is upregulated in different type of cancers and is involved in tumor growth, invasion, migration and resistance to anti-cancer therapy. Interestingly, this Hsp70 upregulation induces Hsp70 re-location into plasma membrane. In this review, the role of Hsp70 in cancer will be discussed focusing particularly on the extracellular membrane-bound Hsp70. The mechanism by which Hsp70 is translocated to plasma membrane of tumor cells and the recent discoveries of drugs targeting this Hsp70 in cancer therapy will be also highlighted.
Collapse
Affiliation(s)
- Mohammed I Y Elmallah
- INSERM 1231, Label Ligue National contre le Cancer and Label d'excellence LipSTIC, 7 Bd Jeanne d'Arc, 21000, Dijon, France; Anti-cancer Center Georges-François Leclerc, Dijon, France; Chemistry Department, Faculty of Science, Helwan University, 11795, Ain Helwan, Cairo, Egypt.
| | - Marine Cordonnier
- INSERM 1231, Label Ligue National contre le Cancer and Label d'excellence LipSTIC, 7 Bd Jeanne d'Arc, 21000, Dijon, France; Faculty of Medicine. University of Burgundy-Franche-Comté, France
| | - Valentin Vautrot
- INSERM 1231, Label Ligue National contre le Cancer and Label d'excellence LipSTIC, 7 Bd Jeanne d'Arc, 21000, Dijon, France; Anti-cancer Center Georges-François Leclerc, Dijon, France; University of Bourgogne Franche-Comté, EA 3181, France
| | - Gaëtan Chanteloup
- INSERM 1231, Label Ligue National contre le Cancer and Label d'excellence LipSTIC, 7 Bd Jeanne d'Arc, 21000, Dijon, France; Faculty of Medicine. University of Burgundy-Franche-Comté, France
| | - Carmen Garrido
- INSERM 1231, Label Ligue National contre le Cancer and Label d'excellence LipSTIC, 7 Bd Jeanne d'Arc, 21000, Dijon, France; Anti-cancer Center Georges-François Leclerc, Dijon, France; Faculty of Medicine. University of Burgundy-Franche-Comté, France.
| | - Jessica Gobbo
- INSERM 1231, Label Ligue National contre le Cancer and Label d'excellence LipSTIC, 7 Bd Jeanne d'Arc, 21000, Dijon, France; Anti-cancer Center Georges-François Leclerc, Dijon, France
| |
Collapse
|
14
|
Wang X, Lane BA, Eberth JF, Lessner SM, Vyavahare NR. Gold nanoparticles that target degraded elastin improve imaging and rupture prediction in an AngII mediated mouse model of abdominal aortic aneurysm. Theranostics 2019; 9:4156-4167. [PMID: 31281538 PMCID: PMC6592177 DOI: 10.7150/thno.34441] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/26/2019] [Accepted: 03/28/2019] [Indexed: 12/20/2022] Open
Abstract
Background: Abdominal aortic aneurysms (AAA) are characterized by a progressive disruption and weakening of the extracellular matrix (ECM) leading to dilation of the aorta which can be fatal if not treated. Current diagnostic imaging modalities provides little insight on the varying degree of ECM degeneration that precedes rupture in AAAs. Targeted delivery of contrast agents such as gold nanoparticles (GNPs) that bind to degraded matrix could prove useful when combined with computed tomography (CT) to provide a non-invasive surrogate marker of AAA rupture potential. Methods: AAAs were induced by chronic infusion of angiotensin II (AngII) into low density-lipoprotein receptor-deficient (LDLr -/-) mice in combination with a high-fat diet. Abdominal ultrasound was used to monitor disease progression and to assess the circumferential strain throughout the cardiac cycle. At six weeks, GNPs conjugated with an elastin antibody (EL-GNP) were injected retro-orbitally. Mice were euthanized 24 hours after EL-GNP injection, and aortas were explanted and scanned ex-vivo with a micro-CT system. Histological assessment and 3D models of the aneurysms with micro-CT were used to determine the EL-GNPs distribution. Isolated vessel burst pressure testing was performed on each aneurysmal aorta to quantify rupture strength and to assess rupture location. Results: Aneurysms were found along the suprarenal aorta in AngII infused mice. Darkfield microscopy indicated EL-GNPs accumulation around the site of degraded elastin while avoiding the healthy and intact elastin fibers. Using nonlinear regression, the micro-CT signal intensity of EL-GNPs along the suprarenal aortas correlated strongly with burst pressures (R2=0.9415) but not the dilation as assessed by ultrasound measurements. Conclusions: Using an established mouse model of AAA, we successfully demonstrated in vivo targeting of EL-GNPs to damaged aortic elastin and correlated micro-CT-based signal intensities with burst pressures. Thus, we show that this novel targeting technique can be used as a diagnostic tool to predict the degree of elastin damage and therefore rupture potential in AAAs better than the extent of dilation.
Collapse
|
15
|
Koç MM, Aslan N, Kao AP, Barber AH. Evaluation of X-ray tomography contrast agents: A review of production, protocols, and biological applications. Microsc Res Tech 2019; 82:812-848. [PMID: 30786098 DOI: 10.1002/jemt.23225] [Citation(s) in RCA: 38] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/21/2018] [Revised: 01/02/2019] [Accepted: 01/12/2019] [Indexed: 12/25/2022]
Abstract
X-ray computed tomography is a strong tool that finds many applications both in medical applications and in the investigation of biological and nonbiological samples. In the clinics, X-ray tomography is widely used for diagnostic purposes whose three-dimensional imaging in high resolution helps physicians to obtain detailed image of investigated regions. Researchers in biological sciences and engineering use X-ray tomography because it is a nondestructive method to assess the structure of their samples. In both medical and biological applications, visualization of soft tissues and structures requires special treatment, in which special contrast agents are used. In this detailed report, molecule-based and nanoparticle-based contrast agents used in biological applications to enhance the image quality were compiled and reported. Special contrast agent applications and protocols to enhance the contrast for the biological applications and works to develop nanoparticle contrast agents to enhance the contrast for targeted drug delivery and general imaging applications were also assessed and listed.
Collapse
Affiliation(s)
- Mümin Mehmet Koç
- School of Engineering, University of Portsmouth, Portsmouth, United Kingdom.,Department of Physics, Kirklareli University, Kirklareli, Turkey
| | - Naim Aslan
- Department of Metallurgical and Materials Engineering, Munzur University, Tunceli, Turkey
| | - Alexander P Kao
- School of Engineering, University of Portsmouth, Portsmouth, United Kingdom
| | - Asa H Barber
- School of Engineering, London South Bank University, London, United Kingdom
| |
Collapse
|
16
|
Reindl J, Shevtsov M, Dollinger G, Stangl S, Multhoff G. Membrane Hsp70-supported cell-to-cell connections via tunneling nanotubes revealed by live-cell STED nanoscopy. Cell Stress Chaperones 2019; 24:213-221. [PMID: 30632067 PMCID: PMC6363613 DOI: 10.1007/s12192-018-00958-w] [Citation(s) in RCA: 22] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/16/2018] [Revised: 11/19/2018] [Accepted: 12/03/2018] [Indexed: 01/19/2023] Open
Abstract
Heat shock protein Hsp70 (Hsp70) is found on the cell surface of a large variety of human and mouse tumor cell types including U87, GL261 glioblastoma, and 4T1 mammary carcinoma cells. We studied the role of membrane-bound Hsp70 (mHsp70) in the formation of cell-to-cell connections via tunneling nanotubes (TNTs) using live-cell STED nanoscopy. This technique allows the visualization of microstructures in the 100-nm range in the living cells. We could show that the presence of tumor-derived mHsp70 in TNTs with a diameter ranging from 120 to 140 nm predominantly originates from cholesterol-rich-microdomains containing the lipid compound globoyltriaosylceramide (Gb3). Under non-stress conditions, Hsp70 and Gb3 are structurally clustered in the membrane of TNTs of tumor cells that showed tumor type specific variations in the amount of cell-to-cell connection networks. Furthermore depletion of cholesterol and ionizing radiation as a stress factor results in a complete loss of Hsp70-containing TNTs.
Collapse
Affiliation(s)
- Judith Reindl
- Universität der Bundeswehr München, Werner-Heisenberg-Weg 39, 85577 Neubiberg, Germany
| | - Maxim Shevtsov
- Center for Translational Cancer Research (TranslaTUM), Klinikum rechts der Isar, Technischen Universität München (TUM), Ismaningerstrasse 22, 81675 Munich, Germany
- Institute of Cytology of the Russian Academy of Sciences (RAS), Tikhoretsky ave. 4, St. Petersburg, 194064 Russia
- Pavlov First Saint Petersburg State Medical University, L’va Tolstogo str. 6/8, St. Petersburg, 197022 Russia
- Polenov Russian Scientific Research Institute of Neurosurgery, Mayakovskogo str. 12, St. Petersburg, 191104 Russia
| | - Günther Dollinger
- Universität der Bundeswehr München, Werner-Heisenberg-Weg 39, 85577 Neubiberg, Germany
| | - Stefan Stangl
- Center for Translational Cancer Research (TranslaTUM), Klinikum rechts der Isar, Technischen Universität München (TUM), Ismaningerstrasse 22, 81675 Munich, Germany
| | - Gabriele Multhoff
- Center for Translational Cancer Research (TranslaTUM), Klinikum rechts der Isar, Technischen Universität München (TUM), Ismaningerstrasse 22, 81675 Munich, Germany
| |
Collapse
|
17
|
Stangl S, Foulds GA, Fellinger H, Pilkington GJ, Pockley AG, Multhoff G. Immunohistochemical and Flow Cytometric Analysis of Intracellular and Membrane-Bound Hsp70, as a Putative Biomarker of Glioblastoma Multiforme, Using the cmHsp70.1 Monoclonal Antibody. Methods Mol Biol 2018; 1709:307-320. [PMID: 29177668 DOI: 10.1007/978-1-4939-7477-1_22] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/10/2023]
Abstract
The major stress-inducible 70 kDa heat shock (stress) protein 70 (Hsp70) is frequently overexpressed in highly aggressive tumor cells and thus might serve as a tumor-specific biomarker of aggressive disease. We have previously shown that, in contrast to normal cells, tumor cells present Hsp70 on their plasma membrane. In order to elucidate the role of intracellular and membrane-bound Hsp70 as a potential tumor biomarker in glioblastoma multiforme, herein, we describe protocols for the staining of cytosolic Hsp70 in tumor formalin fixed paraffin-embedded (FFPE) sections using immunohistochemistry, and for plasma membrane-bound Hsp70 by multi-parametric flow cytometry using the cmHsp70.1 monoclonal antibody (mAb).
Collapse
Affiliation(s)
- Stefan Stangl
- Department of Radiation Oncology, Klinikum Rechts der Isar, Technische Universität München, Ismaninger Str. 22, Munich, 81675, Germany
| | - Gemma A Foulds
- John van Geest Cancer Research Centre, School of Science and Technology, Nottingham Trent University, Clifton Campus, Nottingham, NG11 8NS, UK
| | - Helena Fellinger
- Department of Radiation Oncology, Klinikum Rechts der Isar, Technische Universität München, Ismaninger Str. 22, Munich, 81675, Germany
| | - Geoffrey J Pilkington
- Brain Tumour Research Centre, Institute of Biomedical and Biomolecular Sciences, School of Pharmacy and Biomedical Sciences, University of Portsmouth, Portsmouth, PO1 2DT, UK
| | - A Graham Pockley
- Department of Radiation Oncology, Klinikum Rechts der Isar, Technische Universität München, Ismaninger Str. 22, Munich, 81675, Germany.,John van Geest Cancer Research Centre, School of Science and Technology, Nottingham Trent University, Clifton Campus, Nottingham, NG11 8NS, UK
| | - Gabriele Multhoff
- Department of Radiation Oncology, Klinikum Rechts der Isar, Technische Universität München, Ismaninger Str. 22, Munich, 81675, Germany. .,CCG-Innate Immunity in Tumor Biology, Helmholtz Zentrum München, Ingolstädter Landstrasse 1, Neuherberg, 85764, Germany.
| |
Collapse
|
18
|
Shevtsov M, Huile G, Multhoff G. Membrane heat shock protein 70: a theranostic target for cancer therapy. Philos Trans R Soc Lond B Biol Sci 2018; 373:rstb.2016.0526. [PMID: 29203711 PMCID: PMC5717526 DOI: 10.1098/rstb.2016.0526] [Citation(s) in RCA: 63] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 06/21/2017] [Indexed: 12/19/2022] Open
Abstract
Members of the 70 kDa stress protein family are found in nearly all subcellular compartments of nucleated cells where they fulfil a number of chaperoning functions. Heat shock protein 70 (HSP70), also termed HSPA1A, the major stress-inducible member of this family is overexpressed in a large variety of different tumour types. Apart from its intracellular localization, a tumour-selective HSP70 membrane expression has been determined. A membrane HSP70–positive tumour phenotype is associated with aggressiveness and therapy resistance, but also serves as a recognition structure for targeted therapies. Furthermore, membrane-bound and extracellularly residing HSP70 derived from tumour cells play pivotal roles in eliciting anti-tumour immune responses. Herein, we want to shed light on the multiplicity of different activities of HSP70, depending on its intracellular, membrane and extracellular localization with the goal to use membrane HSP70 as a target for novel therapies including nanoparticle-based approaches for the treatment of cancer. This article is part of the theme issue ‘Heat shock proteins as modulators and therapeutic targets of chronic disease: an integrated perspective’.
Collapse
Affiliation(s)
- Maxim Shevtsov
- Klinikum rechts der Isar, Department of Radiation Oncology, Technische Universität München, Ismaninger Strasse 22, Munich 81675, Germany.,Institute of Cytology of the Russian Academy of Sciences, Tikhoretsky Avenue, 4, St Petersburg 194064, Russia
| | - Gao Huile
- West China School of Pharmacy, Sichuan University, Chengdu 610041, People's Republic of China
| | - Gabriele Multhoff
- Klinikum rechts der Isar, Department of Radiation Oncology, Technische Universität München, Ismaninger Strasse 22, Munich 81675, Germany
| |
Collapse
|
19
|
Jurj A, Braicu C, Pop LA, Tomuleasa C, Gherman CD, Berindan-Neagoe I. The new era of nanotechnology, an alternative to change cancer treatment. Drug Des Devel Ther 2017; 11:2871-2890. [PMID: 29033548 PMCID: PMC5628667 DOI: 10.2147/dddt.s142337] [Citation(s) in RCA: 100] [Impact Index Per Article: 12.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022] Open
Abstract
In the last few years, nanostructures have gained considerable interest for the safe delivery of therapeutic agents. Several therapeutic approaches have been reported, such as molecular diagnosis, disease detection, nanoscale immunotherapy and anticancer drug delivery that could be integrated into clinical use. The current paper aims to highlight the background that supports the use of nanoparticles conjugated with different types of therapeutic agents, applicable in targeted therapy and cancer research, with a special emphasis on hematological malignancies. A particular key point is the functional characterization of nonviral delivery systems, such as gold nanoparticles, liposomes and dendrimers. The paper also presents relevant published data related to microRNA and RNA interference delivery using nanoparticles in cancer therapy.
Collapse
Affiliation(s)
- Ancuta Jurj
- Research Center for Functional Genomics, Biomedicine and Translational Medicine, University of Medicine and Pharmacy “Iuliu-Hatieganu”, Cluj-Napoca, Romania
| | - Cornelia Braicu
- Research Center for Functional Genomics, Biomedicine and Translational Medicine, University of Medicine and Pharmacy “Iuliu-Hatieganu”, Cluj-Napoca, Romania
| | - Laura-Ancuta Pop
- Research Center for Functional Genomics, Biomedicine and Translational Medicine, University of Medicine and Pharmacy “Iuliu-Hatieganu”, Cluj-Napoca, Romania
| | - Ciprian Tomuleasa
- Research Center for Functional Genomics, Biomedicine and Translational Medicine, University of Medicine and Pharmacy “Iuliu-Hatieganu”, Cluj-Napoca, Romania
- Department of Hematology, The Oncology Institute “Prof Dr Ion Chiricuta”, Cluj-Napoca, Romania
| | - Claudia Diana Gherman
- Practical Abilities, Department of Medical Education, University of Medicine and Pharmacy “Iuliu-Hatieganu”, Cluj-Napoca, Romania
- Department of Medical Education, University of Medicine and Pharmacy “Iuliu Hatieganu”, Cluj-Napoca, Romania
| | - Ioana Berindan-Neagoe
- Research Center for Functional Genomics, Biomedicine and Translational Medicine, University of Medicine and Pharmacy “Iuliu-Hatieganu”, Cluj-Napoca, Romania
- Department of Functional Genomics and Experimental Pathology, The Oncology Institute “Prof Dr Ion Chiricuta”, Cluj-Napoca, Romania
- MedFuture Research Center for Advanced Medicine, University of Medicine and Pharmacy “Iuliu-Hatieganu”, Cluj-Napoca, Romania
| |
Collapse
|
20
|
Radons J. The human HSP70 family of chaperones: where do we stand? Cell Stress Chaperones 2016; 21:379-404. [PMID: 26865365 PMCID: PMC4837186 DOI: 10.1007/s12192-016-0676-6] [Citation(s) in RCA: 377] [Impact Index Per Article: 41.9] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/09/2015] [Revised: 01/29/2016] [Accepted: 01/29/2016] [Indexed: 01/23/2023] Open
Abstract
The 70-kDa heat shock protein (HSP70) family of molecular chaperones represents one of the most ubiquitous classes of chaperones and is highly conserved in all organisms. Members of the HSP70 family control all aspects of cellular proteostasis such as nascent protein chain folding, protein import into organelles, recovering of proteins from aggregation, and assembly of multi-protein complexes. These chaperones augment organismal survival and longevity in the face of proteotoxic stress by enhancing cell viability and facilitating protein damage repair. Extracellular HSP70s have a number of cytoprotective and immunomodulatory functions, the latter either in the context of facilitating the cross-presentation of immunogenic peptides via major histocompatibility complex (MHC) antigens or in the context of acting as "chaperokines" or stimulators of innate immune responses. Studies have linked the expression of HSP70s to several types of carcinoma, with Hsp70 expression being associated with therapeutic resistance, metastasis, and poor clinical outcome. In malignantly transformed cells, HSP70s protect cells from the proteotoxic stress associated with abnormally rapid proliferation, suppress cellular senescence, and confer resistance to stress-induced apoptosis including protection against cytostatic drugs and radiation therapy. All of the cellular activities of HSP70s depend on their adenosine-5'-triphosphate (ATP)-regulated ability to interact with exposed hydrophobic surfaces of proteins. ATP hydrolysis and adenosine diphosphate (ADP)/ATP exchange are key events for substrate binding and Hsp70 release during folding of nascent polypeptides. Several proteins that bind to distinct subdomains of Hsp70 and consequently modulate the activity of the chaperone have been identified as HSP70 co-chaperones. This review focuses on the regulation, function, and relevance of the molecular Hsp70 chaperone machinery to disease and its potential as a therapeutic target.
Collapse
Affiliation(s)
- Jürgen Radons
- Scientific Consulting International, Mühldorfer Str. 64, 84503, Altötting, Germany.
| |
Collapse
|